Surgical Specialties, Biochemistry and Immunology Department, Faculty of Medicine, University of Málaga, 29010 Malaga, Spain.
Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS), Instituto de Investigación Biomédica de Málaga (IBIMA), 29590 Malaga, Spain.
Int J Mol Sci. 2023 Sep 27;24(19):14641. doi: 10.3390/ijms241914641.
Colorectal cancer is the third most diagnosed cancer, behind only breast and lung cancer. In terms of overall mortality, it ranks second due to, among other factors, problems with screening programs, which means that one of the factors that directly impacts survival and treatment success is early detection of the disease. Clusterin (CLU) is a molecular chaperone that has been linked to tumorigenesis, cancer progression and resistance to anticancer treatments, which has made it a promising drug target. However, it is still necessary to continue this line of research and to adjust the situations in which its use is more favorable. The aim of this paper is to review the current genetic knowledge on the role of CLU in tumorigenesis and cancer progression in general, and discuss its possible use as a therapeutic target in colorectal cancer.
结直肠癌是仅次于乳腺癌和肺癌的第三大常见癌症。在总体死亡率方面，它位居第二，这其中的原因有很多，包括筛查项目存在问题等，这意味着直接影响生存和治疗效果的因素之一是早期发现疾病。簇集蛋白 (CLU) 是一种分子伴侣，与肿瘤发生、癌症进展和对癌症治疗的耐药性有关，这使其成为一个很有前途的药物靶点。然而，仍有必要继续这一研究方向，并调整更有利于其使用的情况。本文的目的是综述 CLU 在肿瘤发生和癌症进展中的遗传知识，并讨论其在结直肠癌中作为治疗靶点的可能用途。
